Fifth Third Bancorp Purchases 14,642 Shares of Gilead Sciences, Inc. $GILD

Fifth Third Bancorp grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 393,565 shares of the biopharmaceutical company’s stock after acquiring an additional 14,642 shares during the period. Fifth Third Bancorp’s holdings in Gilead Sciences were worth $43,686,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in GILD. Csenge Advisory Group boosted its holdings in Gilead Sciences by 319.0% in the third quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company’s stock worth $2,375,000 after acquiring an additional 16,288 shares in the last quarter. Cookson Peirce & Co. Inc. raised its position in Gilead Sciences by 249.1% in the 3rd quarter. Cookson Peirce & Co. Inc. now owns 10,045 shares of the biopharmaceutical company’s stock valued at $1,115,000 after buying an additional 7,168 shares during the last quarter. Railway Pension Investments Ltd lifted its stake in Gilead Sciences by 3.1% during the 3rd quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company’s stock valued at $157,139,000 after acquiring an additional 42,200 shares in the last quarter. TriaGen Wealth Management LLC purchased a new position in Gilead Sciences during the 3rd quarter worth $1,274,000. Finally, iA Global Asset Management Inc. grew its stake in shares of Gilead Sciences by 11.6% in the 3rd quarter. iA Global Asset Management Inc. now owns 221,890 shares of the biopharmaceutical company’s stock worth $24,630,000 after acquiring an additional 23,046 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $124.31, for a total value of $372,930.00. Following the completion of the transaction, the chief financial officer directly owned 150,503 shares in the company, valued at approximately $18,709,027.93. The trade was a 1.95% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total value of $372,930.00. Following the sale, the insider owned 103,221 shares in the company, valued at approximately $12,831,402.51. This represents a 2.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 288,891 shares of company stock valued at $40,303,946 in the last quarter. Corporate insiders own 0.27% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Needham & Company LLC raised their price target on shares of Gilead Sciences from $140.00 to $170.00 and gave the company a “buy” rating in a research report on Wednesday, February 11th. Truist Financial lifted their target price on shares of Gilead Sciences from $145.00 to $152.00 and gave the stock a “buy” rating in a research report on Wednesday, February 11th. Scotiabank boosted their target price on Gilead Sciences from $140.00 to $177.00 and gave the stock a “sector outperform” rating in a research note on Wednesday, February 11th. Wall Street Zen downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 23rd. Finally, Oppenheimer boosted their price objective on Gilead Sciences from $128.00 to $165.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 11th. Twenty-three equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $152.50.

Gilead Sciences Stock Performance

Shares of GILD opened at $154.98 on Tuesday. Gilead Sciences, Inc. has a 1 year low of $93.37 and a 1 year high of $157.29. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.68 and a quick ratio of 1.31. The stock’s fifty day moving average price is $130.94 and its two-hundred day moving average price is $122.68. The firm has a market cap of $192.28 billion, a PE ratio of 22.89, a PEG ratio of 2.06 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. During the same quarter last year, the firm posted $1.90 EPS. The firm’s revenue for the quarter was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be issued a $0.82 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend is Friday, March 13th. This represents a $3.28 annualized dividend and a yield of 2.1%. Gilead Sciences’s payout ratio is 46.68%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.